New combo therapy targets Hard-to-Treat bile duct cancer
NCT ID NCT04708067
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 34 times
Summary
This early-phase trial tests a new approach for people with advanced bile duct cancer that has spread. It combines a special type of radiation (given in fewer, stronger doses) with an immunotherapy drug called bintrafusp alfa, which helps the immune system fight cancer. The goal is to find the safest dose and see if the combination can shrink tumors or slow the disease. Only 2 participants were enrolled, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.